MELVILLE, N.Y., March 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative”, "BRTX” or the "Company”) ...

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Ryoncil® (remestemcel-L) the first mesenchymal stromal cell ...

A new discovery has shed new light on the crucial role of the CD47 protein in bone fracture healing. Scientists have ...

INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, ...

A recent study published in Engineering has shed new light on the mechanisms underlying the metastasis of head and neck squamous cell carcinoma (HNSCC). The research identified enolase 2 (ENO2), a ...

Cancer remains a leading cause of death globally, with lung cancer being particularly lethal. Despite advancements in diagnostics and therapies, the ...

Let's see how the market has responded to these announcements. The post 2 ASX 200 biotech stocks announcing big news today ...

These shares are having a tough time on Thursday. But why? The post Why Domain, Mesoblast, Pro Medicus, and Tuas shares are tumbling today appeared first on The Motley Fool Australia.